Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through ...

By Karen Roman ReAlta Life Sciences said it is presenting new data at the American Society of Hematology (ASH) Annual Meeting ...

Stephen D. Nimer, M.D., has been awarded the American Society of Hematology’s (ASH) Mentor Award for 2024. As director ...

Patients with multiple myeloma are living longer, thanks to a host of new immunotherapies and targeted drugs. But there is ...

Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene ...

Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a ...

Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 –– ...

Sumitomo Pharma America, Inc. (SMPA) today presented new clinical data supporting further development of nuvisertib, an investigational small molecule being researched for the treatment of ...

DelveInsight's Hematology Market Insights report provides the current and forecast market analysis, individual leading ...

LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces an oral presentation an ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial ...